pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

158 catalysts · 49 phase 2 completion · 21 phase 2 initiation · 20 phase 1 completion · 13 phase 1 initiation · 11 phase 0 trial completion · 9 phase 3 initiation

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts2026-11-23: 0 catalysts2026-11-24: 0 catalysts2026-11-25: 0 catalysts2026-11-26: 0 catalysts2026-11-27: 0 catalysts2026-11-28: 0 catalysts2026-11-29: 0 catalysts2026-11-30: 0 catalysts2026-12-01: 0 catalysts2026-12-02: 0 catalysts2026-12-03: 0 catalysts2026-12-04: 0 catalysts2026-12-05: 0 catalysts2026-12-06: 0 catalysts
view
agendamonth
hide past →
sort
soonestlatesttypesponsoralpha
TA: ophthalmology×TA: dermatology×TA: pain×TA: immunology×TA: cardiology×TA: womens-health×
type
  • phase 2 completion49
  • phase 2 initiation21
  • phase 1 completion20
  • phase 1 initiation13
  • phase 0 trial completion11
TA: pulmonology×
clear all
  • phase 3 initiation9
  • phase 1 2 completion8
  • phase iv trial initiation6
  • filing5
  • phase 3 completion3
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 27, 2026phase 2 initiation136d agoTianjin Lisheng Pharmaceutical Co Ltd — aminophylline (Phase II Trial Initiation)aminophylline

    Therapy area: Cardiovascular, Respiratory. Indication: Asthma, Bronchitis, Emphysema, Pulmonary Edema

    full page →aminophylline →source: globaldata
    ›Apr 27, 2026phase 2 initiation136d agoBrainBees Solutions Ltd — Babyhug pro soothing relief diaper rash cream (Phase II Trial Initiation)Babyhug pro soothing relief diaper rash cream

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →Babyhug pro soothing relief diaper rash cream →source: globaldata
    ›Apr 27, 2026phase 2 initiation136d agoMahatma Gandhi Medical College and Hospital — rosuvastatin (Phase II Trial Initiation)rosuvastatin

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Myocardial Infarction

    full page →rosuvastatin →source: globaldata
    ›Apr 27, 2026phase 2 initiation136d agoYichun Maternal and Child health Care Hospital — sufentanil (Phase II Trial Initiation)sufentanil

    Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

    full page →sufentanil →source: globaldata
    ›Apr 27, 2026phase 2 initiation136d agoCentral South University Xiangya Hospital 3 — HRS-2129 (Phase II Trial Initiation)HRS-2129

    Therapy area: Central Nervous System. Indication: Pain

    full page →HRS-2129 →source: globaldata
    ›Apr 27, 2026phase 2 initiation136d agoAlfred Health Victoria — amiodarone (Phase II Trial Initiation)amiodarone

    Therapy area: Cardiovascular. Indication: Atrial Fibrillation, Congestive Heart Failure (Heart Failure)

    full page →amiodarone →source: globaldata
    ›Apr 27, 2026phase 2 3 initiation136d agoKLES Dr Prabhakar Kore Hospital & Medical Research Centre — esmolol (Phase II/III Trial Initiation)esmolol

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →esmolol →source: globaldata
    ›Apr 27, 2026phase 3 initiation136d agoSun Pharmaceutical Industries Ltd — ruxolitinib (Phase III Trial Initiation)ruxolitinib

    Therapy area: Dermatology. Indication: Vitiligo

    full page →ruxolitinib →source: globaldata
    ›Apr 27, 2026phase 3 initiation136d agoZhuhai Qiwei Biotechnology Co Ltd — QA-102 (Phase III Trial Initiation)QA-102

    Therapy area: Ophthalmology. Indication: Choroidal Neovascularization, Dry (Atrophic) Macular Degeneration, Geographic Atrophy

    full page →QA-102 →source: globaldata
    ›Apr 27, 2026phase 3 initiation136d agoUniversity of Thessaly — abatacept (Phase III Trial Initiation)abatacept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →abatacept →source: globaldata
    ›Apr 27, 2026phase 3 initiation136d agoSiriraj Hospital — tranexamic acid (Phase III Trial Initiation)tranexamic acid

    Therapy area: Cardiovascular, Dermatology. Indication: Melasma (Chlosma), Venous Thromboembolism

    full page →tranexamic acid →source: globaldata
    ›Apr 27, 2026phase 3 initiation136d agoGan & Lee Pharmaceuticals Co Ltd — bofanglutide (Phase III Trial Initiation)bofanglutide

    Therapy area: Respiratory. Indication: Obstructive Sleep Apnea

    full page →bofanglutide →source: globaldata
    ›Apr 28, 2026phase 1 completion135d agoInternational Bio Service Co Ltd — Bisoprolol fumarate (Phase I Trial Completion)BISOPROLOL FUMARATE

    Therapy area: Cardiovascular. Indication: Hypertension

    full page →BISOPROLOL FUMARATE →source: globaldata
    ›Apr 28, 2026phase 1 completion135d agoBio-Innova Co Ltd — clarithromycin (Phase I Trial Completion)clarithromycin

    Therapy area: Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System, Infectious Disease, Mouth and Dental Disorders, Respiratory. Indication: Abscess, Acne Vulgaris, Acute Bacterial Sinusitis, Acute Bronchitis, Acute Pharyngitis, Bacterial Pneumonia, Bacterial Respiratory Tract Infections, Bartonella Infections, Bronchitis, Carbuncle, Cellulitis, Chlamydia trachomatis Pneumonia, Chronic Bronchitis, Community Acquired Pneumonia, Community-Acquired

    full page →clarithromycin →source: globaldata
    ›Apr 28, 2026phase 1 completion135d agoPolfa Tarchomin SA — empagliflozin (Phase I Trial Completion)SYNJARDY

    Therapy area: Cardiovascular, Metabolic Disorders. Indication: Congestive Heart Failure (Heart Failure), Type 2 Diabetes

    full page →SYNJARDY →source: globaldata
    ›Apr 28, 2026phase 1 initiation135d agoShanghai Argo Pharmaceutical Co Ltd — BW-20805 (Phase I Trial Initiation)BW-20805

    Therapy area: Immunology. Indication: Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

    full page →BW-20805 →source: globaldata
    ›Apr 28, 2026phase 1 initiation135d agoShenzhen MagicRNA Biotech Co Ltd — HN-2302 (Phase I Trial Initiation)HN-2302

    Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)

    full page →HN-2302 →source: globaldata
    ›Apr 28, 2026phase 1 initiation135d agoVirginia Commonwealth University — fluorouracil (Phase I Trial Initiation)Efudex

    Therapy area: Dermatology. Indication: Burns

    full page →Efudex →source: globaldata
    ›Apr 28, 2026phase 2 completion135d agoInonu University — albumin gel- and platelet- rich fibrin (Phase II Trial Completion)albumin gel- and platelet- rich fibrin

    Therapy area: Immunology, Mouth and Dental Disorders. Indication: Inflammation, Periodontal Disease, Periodontitis

    full page →albumin gel- and platelet- rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 completion135d agoArdabil University of Medical Sciences — chorionic gonadotropin (Phase II Trial Completion)chorionic gonadotropin

    Therapy area: Women's Health. Indication: Female Infertility

    full page →chorionic gonadotropin →source: globaldata
    ›Apr 28, 2026phase 2 completion135d agoUniversity of Sao Paulo General Hospital — iloprost (Phase II Trial Completion)iloprost

    Therapy area: Cardiovascular. Indication: Pulmonary Arterial Hypertension

    full page →iloprost →source: globaldata
    ›Apr 28, 2026phase 2 initiation135d agoInstitute of Medical Sciences of the Banaras Hindu University — ropivacaine (Phase II Trial Initiation)ropivacaine ER

    Therapy area: Central Nervous System, Respiratory. Indication: Pleural Disease, Post-Operative Pain

    full page →ropivacaine ER →source: globaldata
    ›Apr 28, 2026phase 2 initiation135d agoTianjin Lisheng Pharmaceutical Co Ltd — dexamethasone acetate (Phase II Trial Initiation)dexamethasone acetate

    Therapy area: Immunology, Respiratory. Indication: Allergic Rhinitis, Inflammation, Transplant Rejection

    full page →dexamethasone acetate →source: globaldata
    ›Apr 28, 2026phase iv trial initiation135d agoRajendra Institute of Medical Sciences — levobupivacaine (Phase IV Trial Initiation)levobupivacaine

    Therapy area: Central Nervous System. Indication: Pain

    full page →levobupivacaine →source: globaldata
    ›Apr 29, 2026phase 1 completion134d agoUniversity of Washington — autologous mitochondria (Phase I Trial Completion)autologous mitochondria

    Therapy area: Cardiovascular. Indication: Cerebrovascular Disease, Ischemia

    full page →autologous mitochondria →source: globaldata
    ›Apr 29, 2026phase 1 initiation134d agoBayer AG — asundexian (Phase I Trial Initiation)asundexian

    Therapy area: Cardiovascular. Indication: Ischemic Stroke

    full page →asundexian →source: globaldata
    ›Apr 29, 2026phase 2 completion134d agoMassachusetts Eye and Ear Infirmary — N-acetylcysteine (Phase II Trial Completion)N-acetylcysteine

    Therapy area: Ophthalmology. Indication: Cataract, Fuchs Endothelial Corneal Dystrophy (FECD)

    full page →N-acetylcysteine →source: globaldata
    ›Apr 29, 2026phase 2 completion134d agoNational Heart Lung and Blood Institute — danazol (Phase II Trial Completion)danazol

    Therapy area: Gastrointestinal, Genetic Disorders, Hematological Disorders, Respiratory. Indication: Cytopenia, Liver Fibrosis, Mutational Disorders, Pulmonary Fibrosis

    full page →danazol →source: globaldata
    ›Apr 29, 2026phase 2 completion134d agoBangalore Medical College and Research Institute — dinoprostone (Phase II Trial Completion)dinoprostone ER

    Therapy area: Dermatology. Indication: Vitiligo

    full page →dinoprostone ER →source: globaldata
    ›Apr 29, 2026phase 2 completion134d agoNational Institute of Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

    Therapy area: Women's Health. Indication: Menorrhagia

    full page →unani medicine →source: globaldata
    ›Apr 29, 2026phase 2 initiation134d agoNefro Avillion Clinical Development LLC — siplizumab (Phase II Trial Initiation)siplizumab

    Therapy area: Immunology. Indication: Kidney Transplant Rejection

    full page →siplizumab →source: globaldata
    ›Apr 29, 2026phase 2 initiation134d agoSawai Man Singh Medical College — phenylephrine (Phase II Trial Initiation)phenylephrine

    Therapy area: Cardiovascular. Indication: Hypotension

    full page →phenylephrine →source: globaldata
    ›Apr 29, 2026phase 2 initiation134d agoKyowa Kirin Co Ltd — KK-4277 (Phase II Trial Initiation)KK-4277

    Therapy area: Immunology. Indication: Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus

    full page →KK-4277 →source: globaldata
    ›Apr 29, 2026phase 2 initiation134d agoShenzhen Resproly Biopharmaceutical Co Ltd — RSN-0402 (Phase II Trial Initiation)RSN-0402

    Therapy area: Respiratory. Indication: Idiopathic Pulmonary Fibrosis, Interstitial Lung Fibrosis

    full page →RSN-0402 →source: globaldata
    ›Apr 29, 2026phase 3 initiation134d agoChia Tai Tianqing Pharmaceutical Group Co Ltd — TQH-2722 (Phase III Trial Initiation)TQH-2722

    Therapy area: Respiratory. Indication: Seasonal Allergic Rhinitis

    full page →TQH-2722 →source: globaldata
    ›Apr 29, 2026phase 3 initiation134d agoAll India Institute of Medical Sciences Bathinda — mitomycin (Phase III Trial Initiation)Jelmyto

    Therapy area: Ophthalmology. Indication: Open-Angle Glaucoma

    full page →Jelmyto →source: globaldata
    ›Apr 29, 2026phase iii iv trial initiation134d agoChettinad Hospital and Research Institute — undisclosed local anesthesia (Phase III/IV Trial Initiation)undisclosed local anesthesia

    Therapy area: Central Nervous System. Indication: Pain

    full page →undisclosed local anesthesia →source: globaldata
    ›Apr 30, 2026constraining patent expiry europe133d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026filing133d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing133d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Choroidal Neovascularization

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing133d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing133d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Retinopathy

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing133d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Macular Edema

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026phase 0 trial completion133d agoKunming Yan'an Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Pain

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion133d agoRuijin Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Dermatology. Indication: Burns, Pain, Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion133d agoSecond Affiliated Hospital of Anhui Medical University — yingtao shujie paste (Phase 0 Trial Completion)yingtao shujie paste

    Therapy area: Oncology, Women's Health. Indication: Breast Cancer, Breast Hyperplasia

    full page →yingtao shujie paste →source: globaldata
    ›Apr 30, 2026phase 0 trial completion133d agoCivil Aviation General Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Cardiovascular, Respiratory. Indication: Ischemia Reperfusion Injury, Lung Disease

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion133d agoShanghai Jiao Tong University — insulin (Phase 0 Trial Completion)insulin

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →insulin →source: globaldata
    ›Apr 30, 2026phase 0 trial completion133d agoFoundation for the Promotion of Health and Biomedical Research of Valencia — Aquacel Ag + (Phase 0 Trial Completion)Aquacel Ag +

    Therapy area: Dermatology. Indication: Pressure Ulcers

    full page →Aquacel Ag + →source: globaldata
    ›Apr 30, 2026phase 0 trial completion133d agoHefei First People’s Hospital — ergothioneine (Phase 0 Trial Completion)ergothioneine

    Therapy area: Cardiovascular. Indication: Atherosclerosis

    full page →ergothioneine →source: globaldata
    ← prev
    page 2 of 4
    next →
    $CPIX6.2900-4.98%